FLT3 Expression serves as an inclusion eligibility criterion in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain FLT3 Expression as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).
Trials with FLT3 Expression in the inclusion eligibility criteria most commonly target acute myeloid leukemia .
Amg 553 and anti-flt3 monoclonal antibody 4g8-sdiem are the most frequent therapies in trials with FLT3 Expression as an inclusion criteria .
Significance of FLT3 Expression in Diseases
Acute Myeloid Leukemia +
FLT3 is mutated in 11.3% of acute myeloid leukemia patients .
FLT3 Expression is an inclusion criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain FLT3 Expression and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) .
Amg 553 and anti-flt3 monoclonal antibody 4g8-sdiem are the most frequent therapies in trials for acute myeloid leukemia that contain FLT3 Expression .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.